ArticleRSC advances2025
Copper(ii) chelates of a coumarin-based acyl hydrazone ligand: structural characterization and computational evaluations for prospective applications in antimicrobial, antiviral, antioxidant, and anticancer therapies.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Rationally designed copper-deferiprone-phenanthroline complex as a dual anticancer and SARS-CoV-2 inhibitor.RSC advances · 2026Article
- Solvatochromic, spectroscopic, DFT calculations, antimicrobial and docking studies of new Fe(III), Co(II), and Ni(II) chelates containing 1,2,4-triazine.Scientific reports · 2026Article
- Synthesis, Crystal Structure, Antitumor, and Antimicrobial Activity of Novel Copper(II) Complexes with a Coumarin Derivative Containing a Histamine Substituent.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study represents the synthesis and comprehensive characterization of four novel copper(ii) chelates (CuR, CuRCT, CuH, and CuHCT) derived from a newly developed coumarin-based acyl hydrazone ligand (HCBH). The chelates were prepared using multidisciplinary synthetic routes, including reflux and hydrothermal methods with or without surfactant assistance, resulting in distinct mono- and binuclear structures with nanoscale morphologies. Structural analyses confirmed that all copper complexes possess tetrahedral geometries, with ligand coordination modes varying between tridentate and tetradentate depending on the synthetic method. TEM imaging revealed unique morphologies for each chelate, and the successful dispersion of the bioactive CuH chelate into silica yielded a porous nanostructured drug delivery system. Biological evaluations revealed promising antimicrobial activity, particularly for CuHCT against
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.